[The management of stage I lymphomas of the T-cell type].
Between 1980 and 1988, we treated 68 patients with clinical stage I non-Hodgkin lymphomas. Fifteen patients had lesions classified as T-cell type lymphomas, and the remainder as B-cell type lymphomas. The actuarial 5-year survival rate was 42% for patients with T-cell type and 78% for patients with B-cell (p less than 0.03), and freedom from relapse was 25% and 67%, respectively (p less than 0.01). The main relapse sites for patients with T-cell type were extranodal (5 patients) and multiple sites (2 patients). These results suggest that patients with T-cell type lymphomas should be treated by aggressive combination chemotherapy as well as radiotherapy, even though their disease may appear to be limited to one region.